ArticleInflammation2025
Angiotensin-(1-7) Mitigates Progression from Acute Kidney Injury to Chronic Kidney Disease Via Renin-Angiotensin System Modulation in a Murine Model.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protective Arm of Renin-Angiotensin System: Evidence of Nephroprotective Effects Against Acute Kidney Injury.Acta physiologica (Oxford, England) · 2026Review
- A comprehensive review on indigenous therapeutic approaches in kidney care using Ayush medicine.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) often progresses to chronic kidney disease (CKD), presenting a significant clinical challenge. The renin-angiotensin system (RAS), particularly the protective arm involving Angiotensin-(1-7) (Ang-(1-7)), offers a potential therapeutic target to mitigate this progression. This study explores the effects of Ang-(1-7) in a murine model of ischemia-reperfusion (I/R) injury-induced AKI. Methods. Adult male Balb/c mice were subjected to bilateral renal I/R injury to induce AKI. Mice were then treated with various doses of Ang-(1-7). Key methods included enzyme-linked immunosorbent assay (ELISA) for serum biomarkers, immunohistochemistry for tissue-specific protein expression, and Western blotting for signaling pathway analysis. Key endpoints included serum levels of Angiotensin II (Ang II), Transforming Growth Factor-β1 (TGF-β1), Collagen I, and Superoxide Dismutase (SOD). Results. Ang-(1-7) treatment significantly reduced serum Ang II and TGF-β1 levels and decreased renal Collagen I expression. Notably, a dose-dependent increase in SOD was observed, indicating enhanced antioxidant defense. Additionally, Ang-(1-7) administration led to a marked reduction in renal fibrosis markers and inflammatory cytokines, including TGF-β1 and Collagen I, particularly in the high-dose group. The treatment also modulated the expression of key proteins involved in the RAS pathway, such as increased Angiotensin-Converting Enzyme 2 (ACE2) and decreased Angiotensin II Receptor Type 1 (AT1R) expression. Conclusion. This study highlights the novel therapeutic potential of Ang-(1-7) in preventing AKI progression to CKD by modulating the RAS towards a protective state. The findings provide a strong rationale for further clinical investigation of Ang-(1-7) or Mas receptor agonists as viable therapeutic strategies in kidney disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.